Drug profile · INN
pomalidomide
POMALIDOMIDE SANDOZ
pomalidomide (POMALIDOMIDE SANDOZ) is a crl4(crbn) e3 ubiquitin ligase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — pomalidomide
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- ORAL
- Patents
- 0
- Programs
- 32
- Data quality
- 0.89
Quick answer
pomalidomide (POMALIDOMIDE SANDOZ) is a crl4(crbn) e3 ubiquitin ligase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
CRL4(CRBN) E3 ubiquitin ligase inhibitor
Primary target: CRL4(CRBN) E3 ubiquitin ligase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is pomalidomide?
pomalidomide (POMALIDOMIDE SANDOZ) is a crl4(crbn) e3 ubiquitin ligase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for pomalidomide?
POMALIDOMIDE SANDOZ is a marketed brand name for pomalidomide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pomalidomide?
pomalidomide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.